September 20, 2008

Print this page

Session III

Abdominal Aortic Aneurysms Session : genetics, pathophysiology and clinical studies

Part one

Moderators : G. Cockerill, G. Tromp

8h30
Abdominal aortic aneurysms are deep, deadly and genetic.
H. Kuivaniemi
8h50
Evidence for autoimmunity in the AAA.
D. Tilson

9h10
Aneurysm or occlusive disease-factors determining the clinical course of atherosclerosis of the infrarenal aorta.
BT. Baxter

9h30
Role of the inflammatory cells during the development of the aortic aneurysms.
RW. Thompson

9h50
The role of the mural thrombus during the development and rupture of AAA.
J. Swedenborg

10h10 – 10h30 Discussion

10h30 – 11h00 Coffee Break

Part two

Moderators : J. Lindholt, H. Massin

11h00
Natural history of unoperated AAA.
F. Lederle


11h20
Benefits of screening for abdominal aortic aneurysms concerning ruptures, operations and mortality - a metaanalysis.
J. Lindholt

11h40
From phenotype to genotype ?
J. Powell

12h00 – 12h20 Discussion

12h20 14h00 Lunch
14h00
Serological biomarkers of progression and rupture of abdominal aortic aneurysms.
S. Urbonavicius
14h20
Functional imaging of AAA.
N. Sakalihasan

14h40
Treatment of AAA in high-risk patients : Open repair or EVAR ?
F. Lederle

15h00
Late results of endovascular aneurysm repair versus open aneurysm repair.
J. Blankensteijn

15h20
The place of the endovascular treatment of AAA today: a Scandinavian point of view.
L. Lonn

15h40 16h05 Discussion

16h05 16h30 Coffee Break

 

Session IV

New treatment options for aortic aneurysms

Moderators : E. Steinmetz, B.T. Baxter

16h30
Medical treatment of the Marfan disease.
G. Jondeau
16h50
Pharmacological therapy of AAA (in animals).
K. Yoshimura

17h10
Endovascular cell therapy of AAA.
E. Allaire

17h30
Could abdominal aortic aneurysms be treated medically (clinical trials) ?
BT. Baxter

17h50 – 18h10 Discussion

18h10
Closing remarks
J. Powell & H. Kuivaniemi

 

↑ Top